logo
Allergic to cats or dogs but still want them as pets? Here's tips to help get relief.

Allergic to cats or dogs but still want them as pets? Here's tips to help get relief.

USA Today21-03-2025
Allergic to cats or dogs but still want them as pets? Here's tips to help get relief.
Show Caption
Hide Caption
How to survive allergy season
Spring is almost here and so is allergy season. Here are five surprising ways to survive spring allergies.
Pet owners who suffer from allergies have a number of options to help relieve their symptoms, from grooming changes to medication.
An allergic reaction to a dog or cat can cause sneezing, nasal congestion, itchy eyes, hives and other symptoms, according to the Mayo Clinic. The symptoms are the body's response to an allergen, such as pet dander.
"When you inhale the allergen or come into contact with it, your immune system responds and produces an inflammatory response in your nasal passages or lungs," the clinic said. "Prolonged or regular exposure to the allergen can cause the ongoing (chronic) airway inflammation associated with asthma."
Dr. Shaan Waqar said allergens come from a pet's saliva, dander and even urine. Waqar, an allergist at ENT and Allergy Associates in Plainview, New York, added there are ways for people to avoid a reaction.
The Cleveland Clinic, an Ohio-based medical research and treatment facility, said about 30% of people in the nation have pet allergies. The clinic added it's twice as likely for a person to be allergic to a cat than a dog.
Clean air in the home: Spring cleaning for clean breathing: How you can improve indoor air quality in your home
Small changes may help relieve pet allergy symptoms
Waqar notes that it's best to avoid bringing a pet home that will cause allergy problems. But existing pet owners may be able to make changes to their routine that can improve their allergy issues.
If people are having allergy symptoms caused by a pet, Waqar suggested restricting where in the home the pet can be. That includes keeping the pet out of bedrooms to avoid prolonged, overnight exposure.
If a person is petting a cat or dog, Waqar suggests thoroughly washing hands with soap and water. For the pet itself, he said regular grooming is needed.
Around the home, he said a vacuum with a HEPA filter can help cut down on allergens.
"They can help trap some of those very small particles that some of the other vacuum cleaners cannot, so that can be very helpful," he said.
Medication can help treat pet allergies
Over-the-counter and prescription medication can help, Waqar said. Those medications include oral antihistamines like Zyrtec and Claritin, and nasal sprays like Flonase, Nasal Court and Azelastine. He added people could experience side effects with the medications, the main one being drowsiness that he said accompanies oral antihistamines.
Doctors could prescribe a combination of antihistamine and steroidal nasal spray if a person isn't getting relief from the other medicated options. Beyond that, he said allergy shots can decrease a person's sensitivity to an allergen.
There are two phases to allergy shots: a build-up and maintenance. Waqar said the build-up phase typically requires weekly shots, then, under a doctor's direction, it converts to the maintenance phase, which would require monthly injections.
Ah-choo: Tired of suffering during allergy season? These tips from an expert may offer relief
"You're trying to maintain and hold that protection long-term for the patient, so that hopefully when they stop the allergy shots, the tolerance that they built will stay ‒ so that can be another really effective treatment," he said.
Are there allergy-free cats and dogs?
A truly allergy-free cat or dog does not exist, according to the American College of Allergy, Asthma and Immunology.
But there are some breeds known for being more tolerable for people with allergies. The American Kennel Club said less-allergenic purebred dogs do exist such as poodles, Yorkshire terriers, Bichon frise, Maltese and schnauzers.
Contact reporter Krystal Nurse at knurse@USATODAY.com. Follow her on X @KrystalRNurse, and on BlueSky @krystalrnuse.bsky.social.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Analysis-Wall Street sees new obesity pills as priced near Wegovy and Zepbound
Analysis-Wall Street sees new obesity pills as priced near Wegovy and Zepbound

Yahoo

time13 minutes ago

  • Yahoo

Analysis-Wall Street sees new obesity pills as priced near Wegovy and Zepbound

By Maggie Fick and Bhanvi Satija SEATTLE (Reuters) -U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with their weight-loss injections, analysts and investors say, in a departure from the usual practice of charging more for new medicines despite pressure to cut prices. Neither drugmaker has disclosed pricing plans for their new daily oral medications. With regulatory approvals and launches still months away, pricing plans could change. Denmark-based Novo expects approval later this year and to launch soon after, while Indianapolis-based Lilly expects to launch by August 2026. Novo's Wegovy and Lilly's Zepbound, administered as weekly injections, are the only highly effective weight-loss drugs targeting the GLP-1 hormone, and the United States is their biggest market. U.S. list prices are about $1,000 per month or more, with both companies offering a monthly supply for $499 to customers paying cash rather than using health insurance. Both companies have said they developed oral weight-loss drugs to meet patient needs and widen access to the market, mindful that some people are averse to injections. The pills, however, are not more effective than the injections. Lilly said this month its pill orforglipron cut weight by 12.4% after 72 weeks in a trial. That compares with weight loss of 15% for Novo's daily oral semaglutide. Both trail Lilly's injection at up to 21%. UBS analyst Trung Huynh said that will cap Lilly's pricing. The price is "probably going to come on par with the current drugs today or slightly lower," Huynh said. TD Cowen analyst Michael Nedelcovych said he expects Novo's pill to debut near Wegovy's price, citing the precedent of its diabetes pill Rybelsus being priced at parity with injection Ozempic, the diabetes-treatment version of Wegovy. Novo executives told analysts this month they were not in a hurry for discount pricing for the new pill. Oral GLP-1 drugs will fill a niche rather than displace injections, according to analysts. TD Cowen estimates that pills will account for a percentage share of the global obesity drug market in the mid-teens by 2030, which could reach $150 billion by then. GROWING CASH PAY U.S. doctors, patients and insurers are pressing for lower prices to make the weight-loss drugs more affordable for the 40% of Americans who are obese. Typically, drugmakers launch new drugs at higher prices, citing scientific advances. President Donald Trump and lawmakers from both parties have urged the companies to reduce U.S. prices. Novo declined to comment on pricing, pointing to August 6 comments by David Moore, its U.S. operations head, saying that the company may tap customers paying cash directly via its new NovoCare pharmacy, which was launched this year to sell Wegovy outside of insurance. A Lilly spokesperson called it premature to comment on pricing and launch plans for its pill because the company has not yet submitted data for regulatory approval. Peak annual sales forecasts for Lilly's orforglipron fell to as low as $10 billion after its trial data from earlier estimates of up to $30 billion, according to a Reuters review of analyst estimates. HSBC forecasts $15 billion in peak annual sales for Novo's pill, while Barclays expects only $1 billion. MANUFACTURING VOLUME A key question is how much supply will be available at the time of launch. Shortages of injectable GLP-1s in 2023 and 2024 opened the U.S. market to cheaper compounded versions as the manufacturers failed to anticipate the huge demand. "It's all about scale and pricing," said Kevin Gade, portfolio manager at Bahl & Gaynor, which owns Lilly shares. Gade pointed to Novo's manufacturing challenge. The pill form requires about 75 times more active ingredient than the highest-dose Wegovy injection, two analysts told Reuters. Lilly has said it already has $808.5 million in orforglipron inventory for next year's expected launch. Novo has said it will launch its pill without supply constraints after billions of dollars in investment to expand semaglutide production. Despite the high production needs, Novo is unlikely to debut its pill at a higher price than Wegovy, said Karen Andersen, healthcare strategist at Morningstar. "Particularly in the growing cash-pay market, I doubt it can risk a launch at a premium to Wegovy," Andersen added. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Cohesys Announces First-in-Human Use of Investigational BoneTape™ in Craniofacial Fracture Repair
Cohesys Announces First-in-Human Use of Investigational BoneTape™ in Craniofacial Fracture Repair

Business Wire

time40 minutes ago

  • Business Wire

Cohesys Announces First-in-Human Use of Investigational BoneTape™ in Craniofacial Fracture Repair

TORONTO--(BUSINESS WIRE)--Cohesys Inc., a Toronto-based medical device developer of resorbable fixation technologies, today announced that the first participants have undergone treatment with BoneTape™, an investigational device designed for the fixation of non-load-bearing craniofacial fractures. The procedures were completed as planned and mark the first clinical use of this drill- and screw-free fixation system. "Reaching this milestone is significant for Cohesys as we evaluate BoneTape's potential to offer a simpler, patient-friendly approach to fracture repair,' said Dr. Michael Floros, CEO of Cohesys. 'The data from this study will inform our regulatory strategy and commercialization pathway.' 'This marks an exciting step forward for the study, and it's a privilege to be part of an effort exploring new techniques in facial-fracture treatment,' said Dr. Jeffrey A. Fialkov, MD, MSc, FRCSC, Head of the Division of Plastic and Reconstructive Surgery at Sunnybrook Health Sciences Centre, Associate Professor in the Department of Surgery at the University of Toronto, and Principal Investigator for the study. 'BoneTape's hardware-free approach is intended to simplify surgery and may improve the recovery experience for patients.' Device- and procedure-related risks—including infection, non-union, and re-operation—will be actively monitored throughout the study's follow-up period. Dr. Janaina Bortolatto, VP, Clinical Operations for Cohesys noted, 'The completion of these first cases with BoneTape reflects the dedication of our team and our clinical partners. We are focused on gathering the clinical data needed to evaluate BoneTape for potential future use.' BoneTape is applied with a handheld applicator that affixes the resorbable fixation device to bone surfaces without drilling or screws. The study will determine whether this design performs as intended, potentially sparing patients from device-related complications and the need for hardware-removal procedures. About Cohesys Cohesys Inc. develops advanced resorbable fixation solutions aimed at simplifying surgery and improving bone healing. BoneTape, the company's primary technology, is currently under clinical investigation. For more information, visit BoneTape™ is a trademark of Cohesys Inc. Regulatory Status BoneTape is an investigational device; it is not licensed for commercial sale. Its use in this clinical study has been authorized by Health Canada under an Investigational Testing Authorization (ITA). Safety and effectiveness have not been established. Identifier: NCT06600854

Yale study finds suicide-prevention app effective for psychiatric inpatients
Yale study finds suicide-prevention app effective for psychiatric inpatients

Yahoo

timean hour ago

  • Yahoo

Yale study finds suicide-prevention app effective for psychiatric inpatients

A new study conducted by researchers at Yale School of Medicine and The Ohio State University Wexner Medical Center and College of Medicine has determined that a mobile phone app providing suicide-specific therapy decreased suicidal thoughts among high-risk psychiatric patients. According to the research, the mobile therapy app OTX-202 cut the rate of post-discharge suicide attempts by 58.3% among patients with a history of such behavior. Researchers described this as a significant breakthrough for a population prone to repeated suicidal tendencies. Beyond preventing attempts, the app also helped sustain reductions in suicidal thoughts for up to 24 weeks after psychiatric hospitalization. By comparison, patients using a control app alongside standard treatment initially improved, but their suicidal thoughts returned by week 24. In the wake of the study's findings, the team behind it claims OTX-202 could be a valuable tool for maintaining mental health gains during the vulnerable period following discharge. Targeted therapy crucial as suicide rates increase In the US, suicide ranks among the leading causes of death, with its impact felt across multiple age groups. It is the second leading cause of death for those aged 10–14 and 25–34, the third for individuals aged 15–24, and the fourth for people aged 35–44. Over the past two decades, the national suicide rate has climbed by more than 33%, underscoring the urgent need for effective prevention strategies, the study outlines. More than one million adults in the US engage in nonfatal suicidal behavior each year, with nearly 500,000 hospitalized. Suicide and attempts at taking one's own life cost an estimated $500 billion annually, yet it remains the only leading cause of death without approved prescription treatments for most at-risk patients. According to the study's co-first author Craig Bryan, professor at Ohio State University's Department of Psychiatry and Behavioral Health and director of its suicide prevention program, suicide-specific therapy can be highly effective at reducing suicidal thoughts and urges, but access to trained therapists after hospital discharge is often limited. The mobile app OTX-202 may help close this gap by delivering targeted therapy directly to patients, supporting their recovery and reducing the risk of relapse during the critical post-discharge period. Multi-site randomized trial revealed promising results As part of a multi-site, double-blind randomized controlled trial, researchers from Yale and Ohio State evaluated OTX-202 among 339 psychiatric inpatients across six US hospitals. Participants were assigned either to the OTX-202 app or to an active control app, while being administered standard care. While the control app offered safety planning and psychoeducation, OTX-202 delivered a targeted suicide-specific therapy module. Results showed that patients using OTX-202 were significantly more likely to improve, as measured by the Clinical Global Impression for Severity of Suicide-Change (CGI-SSC) scale—a standardized clinician-rated tool for tracking symptom severity and progress across diverse settings. "Patients and those who care for them do not have access to reliable and effective tools and resources to reduce future suicide risk. This population faces arguably the biggest gap in access to effective interventions of any leading killer. The potential clinical and population health impact of this new option is extraordinary," stated senior author Seth Feuerstein, MD, assistant clinical professor of psychiatry at Yale, in a media release issued by the university.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store